QIAGEN Announces Discontinuation of NeuMoDx, Updates 2024 Forecast
QIAGEN Navigates Exiting NeuMoDx and Adjusting 2024 Outlook
Strategic Shift and Financial Adjustment Sviatlana Zyhmantovich QIAGEN (NYSE:QGEN) shook investors today with the announcement of the discontinuation of its NeuMoDx integrated PCR testing system alongside an update on its 2024 forecast. The medtech company revealed a revised 2024 adjusted diluted EPS projection of at least $2.14 at constant exchange rates (CER), marking an increase ...












